pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CBYL719K12301
Phase 3 · small molecule · Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
CBYL719K12301 for Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CBYL719K12301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
- Status
- active
- Trials
- 1